ABBV · 8-K · 20260622PR076067
Guidance / Outlook
AbbVie Inc. · 2026-06-22 · Importance 41 · Surprise 42 · In source text
AbbVie expects the proposed acquisition to be accretive to adjusted diluted earnings per share beginning in 2032. Management also described potential mega-blockbuster peak sales across Apogee’s pipeline, including zumilokibart and APG273, but did not provide a quantified sales forecast. The earnings-accretion outlook depends on the transaction closing and the clinical and commercial advancement of Apogee’s assets. The stated timeframe extends well beyond the expected third-quarter 2026 closing.
Key facts
- The proposed transaction is expected to be accretive to AbbVie’s adjusted diluted earnings per share (EPS) beginning in 2032. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| net_income | positive | contingent | — | The proposed transaction is expected to be accretive to AbbVie’s adjusted diluted earnings per share (EPS) beginning in 2032. |